DK1626973T3 - (1S,5S)-3-(5,6-dichlor-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptan med analgesisk virkning - Google Patents
(1S,5S)-3-(5,6-dichlor-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptan med analgesisk virkningInfo
- Publication number
- DK1626973T3 DK1626973T3 DK04752844.3T DK04752844T DK1626973T3 DK 1626973 T3 DK1626973 T3 DK 1626973T3 DK 04752844 T DK04752844 T DK 04752844T DK 1626973 T3 DK1626973 T3 DK 1626973T3
- Authority
- DK
- Denmark
- Prior art keywords
- diazabicyclo
- pyridinyl
- dichloro
- heptane
- analgesic effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/445,555 US20040242641A1 (en) | 2003-05-27 | 2003-05-27 | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
PCT/US2004/015905 WO2004106342A1 (en) | 2003-05-27 | 2004-05-20 | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1626973T3 true DK1626973T3 (da) | 2011-01-10 |
Family
ID=33450880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04752844.3T DK1626973T3 (da) | 2003-05-27 | 2004-05-20 | (1S,5S)-3-(5,6-dichlor-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptan med analgesisk virkning |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040242641A1 (da) |
EP (1) | EP1626973B1 (da) |
JP (1) | JP4716999B2 (da) |
KR (2) | KR101238281B1 (da) |
CN (1) | CN1826344B (da) |
AT (1) | ATE485296T1 (da) |
AU (1) | AU2004243270B2 (da) |
BR (1) | BRPI0410808A (da) |
CA (1) | CA2526530C (da) |
CY (1) | CY1111946T1 (da) |
DE (1) | DE602004029671D1 (da) |
DK (1) | DK1626973T3 (da) |
ES (1) | ES2352199T3 (da) |
HK (1) | HK1092135A1 (da) |
MX (1) | MXPA05012738A (da) |
NZ (2) | NZ588123A (da) |
PL (1) | PL1626973T3 (da) |
PT (1) | PT1626973E (da) |
SI (1) | SI1626973T1 (da) |
TW (1) | TWI332502B (da) |
WO (1) | WO2004106342A1 (da) |
ZA (1) | ZA200509601B (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1603585A2 (en) * | 2003-03-14 | 2005-12-14 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
US7354937B2 (en) * | 2004-05-21 | 2008-04-08 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane |
US20050261348A1 (en) * | 2004-05-21 | 2005-11-24 | Buckley Michael J | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
EP2083921A2 (en) | 2006-09-04 | 2009-08-05 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
US8222278B2 (en) * | 2008-06-03 | 2012-07-17 | Abbott Laboratories | Treatment of attention-deficit/hyperactivity disorder |
JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ.ベー. | オレキシン受容体調節因子としての縮合複素環式化合物 |
US8680275B2 (en) * | 2009-10-23 | 2014-03-25 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
US8653263B2 (en) | 2009-10-23 | 2014-02-18 | Janssen Pharmaceutica | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
EP2525797A1 (en) * | 2010-01-20 | 2012-11-28 | Abbott Laboratories | Methods for treating pain |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
MD3426251T2 (ro) | 2016-03-10 | 2022-09-30 | Janssen Pharmaceutica Nv | Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478939A (en) * | 1994-07-20 | 1995-12-26 | American Cyanamid Company | (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives |
TR200102162T2 (tr) * | 1999-01-29 | 2001-12-21 | Abbott Laboratories | Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler. |
NZ514021A (en) * | 1999-04-26 | 2001-09-28 | Neurosearch As | Heteroaryl diazacycloalkanes, their preparation and use |
AU781241B2 (en) * | 1999-05-21 | 2005-05-12 | Abbott Laboratories | Heterocyclic substituted aminoazacycles useful as central nervous system agents |
MY137020A (en) * | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
-
2003
- 2003-05-27 US US10/445,555 patent/US20040242641A1/en not_active Abandoned
-
2004
- 2004-05-20 MX MXPA05012738A patent/MXPA05012738A/es active IP Right Grant
- 2004-05-20 JP JP2006533261A patent/JP4716999B2/ja not_active Expired - Fee Related
- 2004-05-20 NZ NZ588123A patent/NZ588123A/en not_active IP Right Cessation
- 2004-05-20 WO PCT/US2004/015905 patent/WO2004106342A1/en active Application Filing
- 2004-05-20 KR KR1020127001475A patent/KR101238281B1/ko not_active IP Right Cessation
- 2004-05-20 PL PL04752844T patent/PL1626973T3/pl unknown
- 2004-05-20 KR KR1020057022595A patent/KR20060015738A/ko active IP Right Grant
- 2004-05-20 CA CA2526530A patent/CA2526530C/en not_active Expired - Fee Related
- 2004-05-20 DE DE602004029671T patent/DE602004029671D1/de active Active
- 2004-05-20 AU AU2004243270A patent/AU2004243270B2/en not_active Ceased
- 2004-05-20 ES ES04752844T patent/ES2352199T3/es active Active
- 2004-05-20 CN CN2004800213271A patent/CN1826344B/zh not_active Expired - Fee Related
- 2004-05-20 SI SI200431546T patent/SI1626973T1/sl unknown
- 2004-05-20 PT PT04752844T patent/PT1626973E/pt unknown
- 2004-05-20 NZ NZ543615A patent/NZ543615A/xx not_active IP Right Cessation
- 2004-05-20 DK DK04752844.3T patent/DK1626973T3/da active
- 2004-05-20 BR BRPI0410808-6A patent/BRPI0410808A/pt not_active IP Right Cessation
- 2004-05-20 AT AT04752844T patent/ATE485296T1/de active
- 2004-05-20 EP EP04752844A patent/EP1626973B1/en not_active Not-in-force
- 2004-05-26 TW TW093114944A patent/TWI332502B/zh not_active IP Right Cessation
-
2005
- 2005-11-28 ZA ZA200509601A patent/ZA200509601B/en unknown
-
2006
- 2006-08-07 HK HK06108741.9A patent/HK1092135A1/xx not_active IP Right Cessation
-
2011
- 2011-01-11 CY CY20111100032T patent/CY1111946T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CY1111946T1 (el) | 2015-11-04 |
HK1092135A1 (en) | 2007-02-02 |
TW200510420A (en) | 2005-03-16 |
CA2526530A1 (en) | 2004-12-09 |
JP2007500220A (ja) | 2007-01-11 |
KR20120014235A (ko) | 2012-02-16 |
BRPI0410808A (pt) | 2006-06-27 |
PT1626973E (pt) | 2010-12-31 |
NZ543615A (en) | 2009-04-30 |
DE602004029671D1 (de) | 2010-12-02 |
CN1826344B (zh) | 2013-03-06 |
EP1626973B1 (en) | 2010-10-20 |
ATE485296T1 (de) | 2010-11-15 |
SI1626973T1 (sl) | 2011-01-31 |
MXPA05012738A (es) | 2006-02-22 |
WO2004106342A1 (en) | 2004-12-09 |
NZ588123A (en) | 2012-04-27 |
CA2526530C (en) | 2013-01-08 |
KR20060015738A (ko) | 2006-02-20 |
AU2004243270B2 (en) | 2009-12-17 |
CN1826344A (zh) | 2006-08-30 |
JP4716999B2 (ja) | 2011-07-06 |
TWI332502B (en) | 2010-11-01 |
KR101238281B1 (ko) | 2013-03-04 |
PL1626973T3 (pl) | 2011-04-29 |
EP1626973A1 (en) | 2006-02-22 |
ZA200509601B (en) | 2006-10-25 |
AU2004243270A1 (en) | 2004-12-09 |
ES2352199T3 (es) | 2011-02-16 |
US20040242641A1 (en) | 2004-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111946T1 (el) | To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας | |
MY133667A (en) | Quinazoline ditosylate salt compounds | |
MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
EP1485381B8 (en) | Azolylaminoazine as inhibitors of protein kinases | |
TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
WO2003057837A8 (en) | Methods for using anti-muc18 antibodies | |
AU2003220299A1 (en) | Azinylaminoazoles as inhibitors of protein kinases | |
AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
AU2003220300A1 (en) | Compositions useful as inhibitors of protein kinases | |
WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
TW200800976A (en) | New compounds for the treatment of neurological, psychiatric or pain disorders | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
EP1631297A4 (en) | TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS | |
MY135829A (en) | Analeptic and drug combinations | |
ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
EP2347767A3 (en) | Immune regulation based on the targeting of early activation molecules | |
ATE286883T1 (de) | Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität | |
TW200616631A (en) | (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane | |
AU2002332488A8 (en) | R-bambuterol, its preparation and therapeutic uses | |
WO2000071102A3 (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
EP1662875A4 (en) | CHELERYTHRINE, ANALOGUES THEREOF AND THEIR USE IN TREATING DISORDER AND OTHER COGNITIVE DISORDERS | |
WO2000076500A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
WO2004016604A3 (en) | Azabicyclic compounds are central nervous system active agents |